News | March 21, 2024
Bristol Myers Squibb completes acquisition of Karuna Therapeutics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
The super-resolution optical technology will accelerate discovery in biomedical research and transform in vitro diagnostics
Subscribe To Our Newsletter & Stay Updated
